Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.32 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 278.18 |
| Open | 280.74 |
| 1-Year Change | 3.37% |
| Day's Range | 276.4 - 282.34 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 277.71 | -1.24 | -0.44% | 278.95 | 283.09 | 276.18 |
| Apr 22, 2025 | 278.18 | 3.23 | 1.17% | 274.95 | 278.57 | 272.70 |
| Apr 21, 2025 | 273.47 | -3.68 | -1.33% | 277.15 | 277.65 | 270.08 |
| Apr 17, 2025 | 276.86 | 0.45 | 0.16% | 276.41 | 278.36 | 268.01 |
| Apr 16, 2025 | 282.58 | -10.37 | -3.54% | 292.95 | 294.24 | 280.96 |
| Apr 15, 2025 | 295.05 | 2.34 | 0.80% | 292.71 | 295.98 | 290.83 |
| Apr 14, 2025 | 293.67 | 8.16 | 2.86% | 285.51 | 294.95 | 283.81 |
| Apr 11, 2025 | 285.77 | 2.32 | 0.82% | 283.45 | 287.52 | 275.49 |
| Apr 10, 2025 | 281.12 | -5.83 | -2.03% | 286.95 | 288.32 | 268.93 |
| Apr 9, 2025 | 290.12 | 22.67 | 8.48% | 267.45 | 291.27 | 267.04 |
| Apr 8, 2025 | 279.92 | -10.08 | -3.48% | 290.00 | 293.74 | 277.41 |
| Apr 7, 2025 | 285.13 | -3.61 | -1.25% | 288.74 | 296.28 | 280.83 |
| Apr 4, 2025 | 293.78 | -16.43 | -5.30% | 310.21 | 310.21 | 293.15 |
| Apr 3, 2025 | 309.91 | -0.79 | -0.25% | 310.70 | 314.45 | 306.59 |
| Apr 2, 2025 | 305.46 | 0.56 | 0.18% | 304.90 | 306.63 | 300.02 |
| Apr 1, 2025 | 306.44 | -3.77 | -1.22% | 310.21 | 312.30 | 304.88 |
| Mar 31, 2025 | 311.19 | 3.78 | 1.23% | 307.41 | 314.65 | 305.37 |
| Mar 28, 2025 | 306.86 | -0.37 | -0.12% | 307.23 | 308.02 | 304.28 |
| Mar 27, 2025 | 304.90 | -0.35 | -0.11% | 305.25 | 307.42 | 303.45 |
| Mar 26, 2025 | 305.56 | -1.25 | -0.41% | 306.81 | 308.83 | 303.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com